HORMONES, AUTACOIDS, NEUROTRANSMITTERS AND GROWTH FACTORS: Edited by Mark Cooper and Merlin ThomasMonocyte chemoattractant protein-1 and the kidneyHaller, Hermann; Bertram, Anna; Nadrowitz, Felix; Menne, JanAuthor Information Department of Nephrology and Hypertension, Medizinische Hochschule Hannover, Hannover, Germany Correspondence to Professor Hermann Haller, Department of Nephrology and Hypertension, Medizinische Hochschule Hannover, Carl-Neuberg-Str.1, 30559 Hannover, Germany. Tel: +0049 511 5326319; fax: +0049 511 552366; e-mail: [email protected] Current Opinion in Nephrology and Hypertension: January 2016 - Volume 25 - Issue 1 - p 42-49 doi: 10.1097/MNH.0000000000000186 Buy Metrics Abstract Purpose of review Recently, initial studies have been carried out in patients using monocyte chemoattractant protein-1 (MCP-1) inhibitors. This review summarizes the known function of MCP-1 in regulating monocytes during inflammation and its role in inflammatory disease of the kidney. Recent findings MCP-1 is one of the first chemokines described and plays an important role in renal inflammatory disease. The function of MCP-1 has been investigated and analyzed in both animal models of renal disease and renal patients. MCP-1 mediates firstly the release of monocytes from the bone marrow, and then generates a gradient in the endothelial glycocalyx to direct monocytes to sites of inflammation, thereby alleviating the migration of blood leukocytes into the inflamed tissue. In addition, MCP-1 has direct signaling effects in monocytes and influences migration, proliferation, and differentiation of leukocytes. Blockade of MCP-1 in several models of renal disease has ameliorated the disease, suggesting that inhibition of MCP-1 is a promising and valid strategy to treat patients with renal inflammatory disease. Summary Understanding the role of MCP-1 in monocyte homeostasis and the implications of MCP-1 inhibition in renal disease will help in designing better diagnostic and therapeutic strategies in patients with inflammatory renal disease. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.